Checkmate Pharmaceuticals... (CMPI)
NASDAQ: CMPI
· Real-Time Price · USD
10.50
0.00 (0.00%)
At close: Apr 24, 2025, 3:47 PM
Company Description
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer.
It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Checkmate Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Aug 7, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Barry A. Labinger |
Contact Details
Address: 245 Main Street Cambridge, Massachusetts United States | |
| Website | https://www.checkmatepharma.com |
Stock Details
| Ticker Symbol | CMPI |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001651431 |
| CUSIP Number | 162818108 |
| ISIN Number | US1628181083 |
| Employer ID | 36-4813934 |
| SIC Code | 2836 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2022 | 15-12B | Filing |
| Jun 07, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jun 07, 2022 | SC 13D/A | [Amend] Filing |
| Jun 03, 2022 | SC 13D/A | [Amend] Filing |
| Jun 03, 2022 | SC 13D | Filing |
| Jun 01, 2022 | EFFECT | Filing |
| May 31, 2022 | 25-NSE | Filing |
| May 31, 2022 | 4 | Filing |
| May 31, 2022 | 4 | Filing |
| May 31, 2022 | 4 | Filing |